PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

9 November 2022 -- The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials